Wanbury Ltd
WANBURY
Company Profile
Business description
Wanbury Ltd is engaged in the business of pharmaceutical and related activities, including research. Some of the company's products include Cpink 50mg tablets, Rabiplus capsules, and Folinine softgels, among others. The company has one segment of activity, namely, Pharmaceuticals and related products. It generates revenue from contracts with customers through the sale of manufactured and traded goods. Geographically, key revenue is generated from outside India.
Contact
Sector 30-A
10th Floor, BSEL Techpark, B Wing
Opposite Vashi Railway Station
Vashi
Navi MumbaiMH400703
INDT: +91 2267942222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
1,382
Stocks News & Analysis
stocks
Anglo American strikes deal to create a new copper giant
We are surprised that Teck agreed to the merger on these terms, and wouldn’t be surprised if there is a twist in the tale.
stocks
The ‘other’ AI chip behemoth that might just be getting started
The magnitude of growth at Broadcom continues to astound us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,071.40 | 9.10 | -0.10% |
| CAC 40 | 7,820.09 | 58.77 | 0.76% |
| DAX 40 | 23,649.45 | 16.50 | 0.07% |
| Dow JONES (US) | 45,490.92 | 220.42 | -0.48% |
| FTSE 100 | 9,263.51 | 38.12 | 0.41% |
| HKSE | 26,086.32 | 113.94 | -0.43% |
| NASDAQ | 21,886.06 | 6.57 | 0.03% |
| Nikkei 225 | 44,372.50 | 534.83 | 1.22% |
| NZX 50 Index | 13,229.15 | 47.09 | -0.35% |
| S&P 500 | 6,532.04 | 19.43 | 0.30% |
| S&P/ASX 200 | 8,805.00 | 8.80 | -0.10% |
| SSE Composite Index | 3,875.31 | 63.09 | 1.65% |